OTCMKTS:EMMA Emmaus Life Sciences (EMMA) Stock Price, News & Analysis → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free EMMA Stock Alerts $0.10 0.00 (0.00%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.10▼$0.1050-Day Range$0.09▼$0.1352-Week Range$0.05▼$0.34Volume2,654 shsAverage Volume19,880 shsMarket Capitalization$6.19 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest Get Emmaus Life Sciences alerts: Email Address Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About Emmaus Life Sciences Stock (OTCMKTS:EMMA)Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. The company was founded in 2000 and is headquartered in Torrance, California.Read More EMMA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EMMA Stock News HeadlinesApril 17, 2024 | msn.comDistrict 11 wrestling: Kinney, Fanelli, Smith earn Scholar-Athlete awardsApril 15, 2024 | finance.yahoo.comEmmaus Life Sciences Reports Delayed Filing of Annual ReportApril 26, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.April 10, 2024 | chicago.suntimes.comThe Museum of Science and Industry closed for mysterious reasons last week. Here’s whyApril 10, 2024 | investing.comEmmaus Life Sciences Inc (EMMA)April 4, 2024 | msn.comPeabody Museum Review: Smearing ScienceMarch 27, 2024 | wsj.comEmmaus Life Sciences Inc.February 24, 2024 | msn.comHomeless charity seeks volunteers to help with eBay operationsApril 26, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.February 23, 2024 | msn.comDiscovery World named one of the best science museums in USA Today's 10Best Readers' Choice AwardsFebruary 22, 2024 | msn.comTexas Tech University Health Sciences Center announces Simulation Program reaccreditationFebruary 18, 2024 | abcnews.go.comSaving democracy is central to Biden's campaign. Will it resonate with voters?February 2, 2024 | finance.yahoo.comEmmaus Life Sciences Receives Marketing Authorization for Puerto RicoFebruary 1, 2024 | msn.comScience Museum of Western Virginia announces grand opening of ‘The Eye’January 18, 2024 | msn.comEmmaus wrestlers roll their way over “flat” FreedomJanuary 17, 2024 | news.yahoo.comTransgender row at Science Museum over claims reworked exhibit is 'even more insidious'January 12, 2024 | msn.comBiden says Austin still has his confidence, but not revealing hospitalization was lapse in judgmentJanuary 8, 2024 | msn.comDenver Museum of Nature & Science gets makeover with East Wing renovation projectJanuary 4, 2024 | sfgate.comA local guide to science museums near San FranciscoJanuary 4, 2024 | msn.comScience Museum of Minnesota receives largest gift in organization's historyNovember 17, 2023 | msn.comThe Museum of Illusions in Philadelphia meets science with immersive funNovember 14, 2023 | cbsnews.comNew exhibit at the Academy of Natural Sciences takes you back millions of years into historyNovember 14, 2023 | finanznachrichten.deEmmaus Life Sciences, Inc.: Emmaus Life Sciences Reports Q3 2023 Financial ResultsNovember 14, 2023 | msn.comEmmaus Life Sciences GAAP EPS of -$0.01, revenue of $5MNovember 14, 2023 | finance.yahoo.comEmmaus Life Sciences Reports Q3 2023 Financial ResultsNovember 10, 2023 | msn.comSeattle nonprofit wants to help all students love math, using school programs and in-person exhibitsNovember 10, 2023 | msn.comBest Museums for Kids in Philly: Children’s Museums and Family-Friendly MuseumsSee More Headlines Receive EMMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Emmaus Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:EMMA CUSIPN/A CIK822370 Webwww.emmausmedical.com Phone(310) 214-0065Fax866-294-2611Employees54Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,620,000.00 Net Margins-16.66% Pretax Margin-16.42% Return on EquityN/A Return on Assets-9.73% Debt Debt-to-Equity RatioN/A Current Ratio0.15 Quick Ratio0.12 Sales & Book Value Annual Sales$18.39 million Price / Sales0.34 Cash FlowN/A Price / Cash FlowN/A Book Value($0.69) per share Price / Book-0.14Miscellaneous Outstanding Shares61,850,000Free Float40,200,000Market Cap$6.19 million OptionableNot Optionable Beta1.61 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Willis C. Lee M.S. (Age 64)Co-President, COO & Chairman of the Board Comp: $240kMr. Yasushi Nagasaki CPA (Age 57)CPA, Chief Financial Officer Comp: $250kMr. George Sekulich (Age 58)Co-President, Chief Commercial Officer & Director Mr. Dale E. Short J.D.Legal Consultant & Corporate SecretaryDr. Charles W. Stark Pharm.D (Age 69)Pharm.D., Senior Vice President of Medical Affairs, Clinical, Regulatory Mr. Kurt H. Kruger M.B.A. (Age 69)M.S., Consultant Comp: $300.02kMore ExecutivesKey CompetitorsAyala PharmaceuticalsNASDAQ:ADXSHoth TherapeuticsNASDAQ:HOTHSonnet BioTherapeuticsNASDAQ:SONNXenetic BiosciencesNASDAQ:XBIOAvenue TherapeuticsNASDAQ:ATXIView All Competitors EMMA Stock Analysis - Frequently Asked Questions How have EMMA shares performed in 2024? Emmaus Life Sciences' stock was trading at $0.1001 at the beginning of 2024. Since then, EMMA stock has decreased by 0.1% and is now trading at $0.10. View the best growth stocks for 2024 here. Are investors shorting Emmaus Life Sciences? Emmaus Life Sciences saw a decrease in short interest in April. As of April 15th, there was short interest totaling 700 shares, a decrease of 12.5% from the March 31st total of 800 shares. Based on an average daily volume of 800 shares, the short-interest ratio is presently 0.9 days. View Emmaus Life Sciences' Short Interest. How do I buy shares of Emmaus Life Sciences? Shares of EMMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:EMMA) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe A.I. story nobody is telling you (Read ASAP)TradeSmithForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Emmaus Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
